Viro - viro - Ravimiamet

stiefel laboratories legacy (ireland) limited - klindamütsiin+bensoüülperoksiid - geel - 10mg+50mg 1g 6g 1tk; 10mg+50mg 1g 15g 1tk; 10mg+50mg 1g 55g 1tk; 10mg+50mg 1g 25g 1tk

Viro - viro - Ravimiamet

radaydrug kft. - kolekaltsiferool - õhukese polümeerikattega tablett - 7000rÜ 4tk; 7000rÜ 8tk; 7000rÜ 12tk

Viro - viro - Ravimiamet

radaydrug kft. - kolekaltsiferool - õhukese polümeerikattega tablett - 1000rÜ 30tk; 1000rÜ 90tk; 1000rÜ 60tk

Viro - viro - Ravimiamet

radaydrug kft. - kolekaltsiferool - õhukese polümeerikattega tablett - 800rÜ 30tk; 800rÜ 60tk; 800rÜ 90tk

Euroopan unioni - viro - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Euroopan unioni - viro - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Viro - viro - Ravimiamet

galderma international - trifaroteen - kreem - 50mcg 1g 15g 1tk; 50mcg 1g 5g 1tk; 50mcg 1g 30g 1tk; 50mcg 1g 75g 1tk

Viro - viro - Ravimiamet

steriscience b.v. - meropeneem - süste-/infusioonilahuse pulber - 1g 10viaal; 1g 1viaal

Viro - viro - Ravimiamet

steriscience b.v. - meropeneem - süste-/infusioonilahuse pulber - 500mg 10viaal

Viro - viro - Ravimiamet

orifarm healthcare a/s - klindamütsiin+bensoüülperoksiid - geel - 10mg+50mg 1g 50g 1tk